Amsterdam 2013 Programme Satellite Meetings Registration Exhibition Virtual Exhibition Hotels Visa Letter Invitation
Search Abstracts by author or title
(results will display both Free Papers & Poster)

Corneal collagen cross-linking can reduce the burden of eye banks

Poster Details

First Author: S.Hassan BANGLADESH

Co Author(s):    N. Gangopadhyay              

Abstract Details



Purpose:

To report the outcome of Corneal Collagen Cross-linking with Riboflavin (C3R / CXL) can stabilize the progress of Keratoconus and can reduce the burden over donor cornea to some extends.

Setting:

Retrospective study by single surgeon in a single cornea service center at Cornea Clinic & Research Center, Harun Eye Foundation Hospital, Dhaka, Bangladesh Study period was from April 2012 to January 2013.

Methods:

This study includes 125 eyes of 80 patients with keratoconus scheduled for standard treatment of corneal collagen cross-linking with riboflavin (C3R / CXL). Corneal thickness of all patents was 400 micro meter or above. All patients were checked for 1. Unaided visual acuity 2. Latest refractive error and corrected visual acuity, 3. Visual acuity with RGP or Rose ┬ľK Contact Lens, 4. Corneal Topography, 5. Pachymetry, 6. Intraocular pressure and 7. Posterior segment evaluation. All those things were checked in every post operative one, three, six, nine and twelve months postoperatively.

Results:

C3R is stabilized the clinical condition of all patients. It also flattens & improves visual acuity 1 to 8 lines in 65% of patients.

Conclusions:

Results of C3R were quite good. The life of keratoconus patient will be more comfortable if we can do this procedure in early stage of this disease. Cornea collection from our Eye Banks in last three years was less than 80 corneas per year whereas we reduce the lode of 125 eyes from donor cornea in last one year by doing C3R.In advance country 15% patients who are demanding donor cornea are keratoconus. So C3R also have a very good role to reduce the lode donor cornea.

Financial Disclosure:

NONE

Back to previous